Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Keiji Oishi (Yamaguchi, Japan), Keiji Oishi, Keisuke Aoe, Yusuke Mimura, Yoriyuki Murata, Kenji Sakamoto, Wataru Koutoku, Tsuneo Matsumoto, Hiroshi Ueoka, Kazuto Mastunaga, Masafumi Yano. Survival from acute exacerbation of idiopathic pulmonary fibrosis with or without direct hemoperfusion with polymyxin B-immobilized fiber column: A retrospective analysis. Eur Respir J 2016; 48: Suppl. 60, 2101

Member's Comments

No comment yet.

Related content which might interest you: Prognostic factors analysis of patients with acute exacerbation of idiopathic interstitial pneumonias treated by polymyxin B hemoperfusion Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Prognostic factors analysis of patients with rapid progressive interstitial pneumonias treated by direct hemoperfusion with polymyxin B-immobilized fiber column Source: International Congress 2014 – ILDs 1 Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 23: 792 Year: 2004 Asymmetry in acute exacerbation of idiopathic pulmonary fibrosis Source: ERJ Open Res, 3 (2) 00036-2016; 10.1183/23120541.00036-2016 Year: 2017 Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm Source: Eur Respir J 2015; 46: 512-520 Year: 2015 Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids Source: Breathe, 16 (3) 200086; 10.1183/20734735.0086-2020 Year: 2020 Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease Source: Eur Respir Rev 2009; 18: 129-132 Year: 2009 Diagnosis and therapy of acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) in Germany Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias Year: 2018 Clinical experience with nintedanib for the treatment of IPF in 80 cases Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Fatal acute exacerbation of idiopathic pulmonary fibrosis: report of 4 cases Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases Year: 2007 Non-invasive ventilation (NIV) in acute respiratory failure in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Outcome of noninvasive ventilatory support in acute and chronic respiratory failure Year: 2015 Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study Source: Eur Respir J 2012; 40: 101-109 Year: 2012 Acute respiratory failure in idiopathic pulmonary fibrosis: is there a role for mechanical ventilation? Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008 Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 40: 93-100 Year: 2012 Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis Source: ERJ Open Res, 6 (4) 00261-2019; 10.1183/23120541.00261-2019 Year: 2020 Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Continuos positive airway pressure by helmet in exacerbation of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Mechanical ventilation and weaning Year: 2013 Mechanical ventilation for acute respiratory failure in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 94s Year: 2004 A proof of concept study by thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Acute exacerbation in combined pulmonary fibrosis and emphysema (CPFE): what special features? Source: Virtual Congress 2020 – Possible scenarios in the challenging future of rare diffuse parenchymal lung diseases Year: 2020